Tag Archives: SHPG

Hot Blue Chip Stocks To Invest In 2018

The word “growth” is the central word in the phrase Dividend Growth Investing, yet DGI often gets a bad rap as a stodgy method of saving for retirement. I think this misperception arises from the fact that some proponents of the strategy (who may be more focused on income than returns) require a certain minimum yield threshold for their investments. This, in turn, screens many of the higher growth companies from their radar, as higher growth companies generally have lower payout ratios than their slower growth counterparts.

As a result, many of the same old slow-growing blue chips like Coca-Cola (NYSE:KO), Proctor & Gamble (NYSE:PG), and General Mills (NYSE:GIS) are widely held and discussed in the “Dividends” section of Seeking Alpha, while other higher growth opportunities are passed over. This is unfortunate, because there are several very high quality companies that are being disqualified simply because of a lower yield.

These lower yield, higher growth companies can be excellent investments for those with an extended time horizon, and even for retirees they can be a nice boost for a portfolio. For all the angst of wanting enough immediate income, a freshly minted retiree should realize that they are also likely looking at a 20 year time frame for their investments. As the ssa.gov life expectancy calculator shows, a male turning 62 years old in 2016 can expect to live an additional 21.6 years.

Hot Blue Chip Stocks To Invest In 2018: Green Mountain Coffee Roasters Inc.(GMCR)

Advisors’ Opinion:

  • [By Jonas Elmerraji]

    As badly as short sellers want to hate on Green Mountain Coffee Roasters (GMCR), betting against the multiyear rally in this $12.7 billion beverage stock has been about as wise as eating from a box with a skull and crossbones on it. And as a bull market continues to lift all ships, Green Mountain’s ship is going to keep floating above the others.

    Green Mountain owns Keurig, the brand of beverage brewers that use self-contained K-Cups to make coffee, teas, and other drinks. While Keurig’s “fad” status has certainly helped tip the deck against GMCR, the fact remains that the firm has done most of the hard work in getting Keurig machines accepted by consumers. With brewers essentially ubiquitous at this point, the firm is able to make money on its cash cow: the K-Cups.

    Keurig’s individual-serving cups have big margins and a big installed base. With huge convenience and the relatively large sunk cost that consumers have put into their Keurig machines, it’s a sticky business with big switching costs. Consumers who buy a Keurig are much less likely to spend the money on a competing brand of proprietary coffee pods.

    I’ve said before that GMCR is far from cheap right now. But its momentum trajectory is showing few signs of fizzling out, especially as direct competitors such as Starbucks (SBUX) continue to sell K-Cups of their own. Don’t bet against GMCR in September – buy this Rocket Stock instead.

  • [By Canadian Value]

    So Im going to stick my next out and share my views on four battleground stocks that are among my favorite shorts: World Acceptance (WRLD), Green Mountain (GMCR), Herbalife (HLF), and InterOil (IOC). And next week at the Value Investing Congress I will present another short, my largest.

  • [By David Sterman]

    But for short sellers in Green Mountain Coffee Roasters (Nasdaq: GMCR), there's another outcome: They've been badly burned as shares have surged, but they insist they've been right all along, and it's only a matter of time before the stock crashes and burns.

Hot Blue Chip Stocks To Invest In 2018: Ternium S.A.(TX)

Advisors’ Opinion:

  • [By Matthew DiLallo]

    Shares of Ternium SA (NYSE:TX) jumped on Wednesday: up more than 10% by 2:30 p.m. EST. While the steelmaker reported weaker-than-expected earnings after the closing bell yesterday, it provided optimistic guidance and announced a compelling acquisition.

Hot Blue Chip Stocks To Invest In 2018: Shire plc(SHPG)

Advisors’ Opinion:

  • [By Max Macaluso and David Williamson]

    At the end of last week, a Bloomberg article revealed that Shire (NASDAQ: SHPG  ) and pharmaceutical giant Sanofi (NYSE: SNY  ) may be circling ViroPharma (NASDAQ: VPHM  ) . The the following video, from The Motley Fool’s health care show Market Checkup, analysts David Williamson and Max Macaluso take a close look at ViroPharma and discuss the recent interest in this small biotech company.

  • [By Ben Levisohn]

    Specialty pharmaceuticals Shire (SHPG) and Mallinckrodt (MNK) soared today following their better-than-expected earnings, while Morgan Stanley worried about Valeant Pharmaceutical International’s (VRX) ability to sell its unwanted assets.

  • [By Ben Levisohn]

    We highlight the key takeaways below, which have read-throughs for brand drug companies we cover such asAllergan (AGN), Shire (SHPG), Valeant Pharmaceuticals International, Mallinckrodt,Endo International and Jazz Pharmaceuticals (JAZZ), among others.

  • [By Todd Campbell]

    The partnered portfolio includes Movantik and Adynovate, which are licensed to AstraZeneca (NYSE:AZN) and Shire (NASDAQ:SHPG), respectively.

    Movantik won Food and Drug Administration approval in September 2014 for use in relievingopioid constipation, and Nektar Therapeutics reports that annual prescriptions jumped 270% year over year in 2016. Currently, Movantik is selling at an annualized clip of about $160 million, and according to the licensing agreement, Nektar Therapeutics receives a 20% plus royalty on U.S. sales, plus potential sales milestone payments.

  • [By Jim Robertson]

    That’s why its worth pointing out that just yesterday, small cap cannabinoid prodrug pharmaceutical stock Vitality Biopharma, Inc. (OTCQB: VBIO) announced the appointment of Tracy Rockney, J.D. to the position of Senior Regulatory Advisor. In addition to being the Co-Founder & Chief Operating Officer of OneSource Regulatory, a regulatory consulting firm, Rockney was previously:

    From May 2010 to May 2015, she was the VP, Regulatory Affairs at AbbVie Inc (NYSE: ABBV) leading the executive functions related to regulatory policy and intelligence. From August 1993 to January 2005, she held positions of increasing responsibility with Pfizer Inc (NYSE: PFE), formerly Wyeth.  From January 2005 to April 2010, she held positions with Shire PLC (NASDAQ: SHPG), including serving as Senior Director, Regulatory Affairs. This included responsibilities as Therapeutic Area Head for Shire’s Gastrointestinal Business Unit, Regulatory Advertising & Promotion and CMC. Rockney led the regulatory team and negotiations with the FDA for LIALDA which are part of the drug class of aminosalicylates that are now part of the clinical standard-of-care for treating inflammatory bowel disease. LIALDA™ was found to be effective in Phase 3 trials for inducing remission of active mild-to-moderate ulcerative colitis after eight weeks of treatment. LIALDA™ (also now marketed as Mezavant®) had 2016 U.S. sales of $714 million – up 16% relative to 2015 sales.

    Rockney’s work for Shire is of particular interest to Vitality Biopharma which has developed a new class of cannabinoid prodrugs (medications or compounds that, after administration, are converted within the body into a pharmacologically active drug), known as cannabosides, which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Cannabosides could provide therapeutic benefits for infl

Hot Blue Chip Stocks To Invest In 2018: Pound/Rand(PX)

Advisors’ Opinion:

  • [By Ben Levisohn]

    The last twelve months haven’t been kind to Praxair (PX) and Air Products & Chemicals (APD), but UBS analyst John Roberts and team argue that’s about to change, as they upgrade their shares to Buy from Neutral arguing that their earnings can withstand a slowing global economy:

    In our view, the two stocks are more alike than different. NTM P/Es are within ~0.5 pts of each other. Both stocks have declined ~20% from their historical highs the largest corrections in 20+ years aside from the financial crisis…

    Industrial gas stocks have normally grown through changes in FX, oil & China demand within normal historical ranges. And investor concerns around China forAir Products & Chemicals may still prove much bigger than reality. Nevertheless, the combination of FX & oil sector impacts on Praxair, and FX & China issues for Air Products & Chemicals, have been much larger than previously seen. With oil already down, the dollar already appreciated, & China concerns already heightened we believe forward basis would appear to carry only normal risks (& lower if FX & oil are mean-reverting, which some theories support).

    Normal high single digit EPS growth projected for both in 2017 vs 2016: Four large firms serve 70%+ of the global merchant gas market, and price normally contributes ~2% to growth. Customer older captive units being outsourced contributes another 2%. Secular drivers for oxygen include energy savings (i.e. O2 burns more efficiently than air), life sciences (healthcare & microbial processes) nitrogen secular drivers include increasing purity requirements (food freezing & semiconductors). Topline growth ~2x global GDP more normal, with EPS growth ~2x sales growth due to high fixed costs (key variable costs are inexpensive air & power).

    Financial crisis demand drop was only a few %, in line with global GDP drop Most chemicals volumes dropped 10%+ (some 40%

Hot Blue Chip Stocks To Invest In 2018: RetailMeNot, Inc.(SALE)

Advisors’ Opinion:

  • [By Demitrios Kalogeropoulos]

    As for individual stocks, RetailMeNot (NASDAQ:SALE) and SUPERVALU (NYSE:SVU) attracted heavy investor interest following merger and acquisition news.

  • [By Lisa Levin]

    Shares of RetailMeNot Inc (NASDAQ: SALE) got a boost, shooting up 12 percent to $8.42. RetailMeNot announced after Thursday’s close it has entered into an agreement to acquire GiftCard Zen, a secondary marketplace for gift cards. The company reported preliminary Q1 revenue of $54 million to $54.5 million and FY16 revenue of $228 million to $241 million.

Hot Blue Chip Stocks To Invest In 2018: Xerium Technologies Inc.(XRM)

Advisors’ Opinion:

  • [By kiplinger]

     52-week high: $18.93 


    52-week low: $11.01 

    Annual revenues: $492.9 million 

    Xerium Technologies (XRM), a manufacturer of products used in papermaking, is a favorite of micro-cap expert Dan Abramowitz, who heads Hillson Financial Management, in Rockville, Md. Abramowitz calls the company “a turnaround story that is now at an inflection point.” Changes that a new management team put into effect in 2012 should start bearing fruit. The stock’s price-earnings ratio is a mere 7, based on the average of analysts’ earnings estimates for 2016.

Hot Clean Energy Stocks To Own For 2018

Ra Pharmaceuticals filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). No pricing details were given in the filing, but in the previous filing the offering was valued up to $86.25 million. The company expects to list its shares on the NASDAQ under the symbol RARX.

The underwriters for the offering are Credit Suisse, Jefferies, BMO Capital Markets and SunTrust Robinson Humphrey.

This clinical-stage biopharmaceutical company uses its proprietary peptide chemistry platform to develop novel therapeutics for the treatment of serious diseases that are caused by excessive or uncontrolled activation of the complement system, a critical component of the immune system. Inappropriate activation of the complement system can quickly turn it from a beneficial defense system to an aggressor that plays a major role in immune and inflammatory diseases.

The company is developing its lead product candidate, RA101495, a convenient self-administered subcutaneous (SC) injection, which is an injection into the tissue under the skin, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).

Hot Clean Energy Stocks To Own For 2018: Shire plc(SHPG)

Advisors’ Opinion:

  • [By Ben Levisohn]

    We highlight the key takeaways below, which have read-throughs for brand drug companies we cover such asAllergan (AGN), Shire (SHPG), Valeant Pharmaceuticals International, Mallinckrodt,Endo International and Jazz Pharmaceuticals (JAZZ), among others.

  • [By Max Macaluso and David Williamson]

    At the end of last week, a Bloomberg article revealed that Shire (NASDAQ: SHPG  ) and pharmaceutical giant Sanofi (NYSE: SNY  ) may be circling ViroPharma (NASDAQ: VPHM  ) . The the following video, from The Motley Fool’s health care show Market Checkup, analysts David Williamson and Max Macaluso take a close look at ViroPharma and discuss the recent interest in this small biotech company.

  • [By Todd Campbell]

    The partnered portfolio includes Movantik and Adynovate, which are licensed to AstraZeneca (NYSE:AZN) and Shire (NASDAQ:SHPG), respectively.

    Movantik won Food and Drug Administration approval in September 2014 for use in relievingopioid constipation, and Nektar Therapeutics reports that annual prescriptions jumped 270% year over year in 2016. Currently, Movantik is selling at an annualized clip of about $160 million, and according to the licensing agreement, Nektar Therapeutics receives a 20% plus royalty on U.S. sales, plus potential sales milestone payments.

  • [By Jim Robertson]

    That’s why its worth pointing out that just yesterday, small cap cannabinoid prodrug pharmaceutical stock Vitality Biopharma, Inc. (OTCQB: VBIO) announced the appointment of Tracy Rockney, J.D. to the position of Senior Regulatory Advisor. In addition to being the Co-Founder & Chief Operating Officer of OneSource Regulatory, a regulatory consulting firm, Rockney was previously:

    From May 2010 to May 2015, she was the VP, Regulatory Affairs at AbbVie Inc (NYSE: ABBV) leading the executive functions related to regulatory policy and intelligence. From August 1993 to January 2005, she held positions of increasing responsibility with Pfizer Inc (NYSE: PFE), formerly Wyeth.  From January 2005 to April 2010, she held positions with Shire PLC (NASDAQ: SHPG), including serving as Senior Director, Regulatory Affairs. This included responsibilities as Therapeutic Area Head for Shire’s Gastrointestinal Business Unit, Regulatory Advertising & Promotion and CMC. Rockney led the regulatory team and negotiations with the FDA for LIALDA which are part of the drug class of aminosalicylates that are now part of the clinical standard-of-care for treating inflammatory bowel disease. LIALDA™ was found to be effective in Phase 3 trials for inducing remission of active mild-to-moderate ulcerative colitis after eight weeks of treatment. LIALDA™ (also now marketed as Mezavant®) had 2016 U.S. sales of $714 million – up 16% relative to 2015 sales.

    Rockney’s work for Shire is of particular interest to Vitality Biopharma which has developed a new class of cannabinoid prodrugs (medications or compounds that, after administration, are converted within the body into a pharmacologically active drug), known as cannabosides, which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Cannabosides could provide therapeutic benefits for infl

  • [By Ben Levisohn]

    Specialty pharmaceuticals Shire (SHPG) and Mallinckrodt (MNK) soared today following their better-than-expected earnings, while Morgan Stanley worried about Valeant Pharmaceutical International’s (VRX) ability to sell its unwanted assets.

Hot Clean Energy Stocks To Own For 2018: Alere Inc.(ALR)

Advisors’ Opinion:

  • [By Lisa Levin]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Thursday’s regular session.

  • [By Lisa Levin]

    In trading on Wednesday, healthcare shares fell by 0.91 percent. Meanwhile, top losers in the sector included Alere Inc (NYSE: ALR), down 8 percent, and Exelixis, Inc. (NASDAQ: EXEL), down 10 percent.

Hot Clean Energy Stocks To Own For 2018: Lifetime Brands Inc.(LCUT)

Advisors’ Opinion:

  • [By Lisa Levin]

    On Monday, cyclical consumer goods & services shares gained by 0.41 percent. Top gainers in the sector included Kandi Technologies Group Inc (NASDAQ: KNDI), Starwood Hotels & Resorts Worldwide Inc (NYSE: HOT), and Lifetime Brands Inc (NASDAQ: LCUT).

stock market online

Ripple prices surged more than 80% Photographer: Chris Ratcliffe/Bloomberg News

Ripple prices have surged in the last few days, building upon their recent gains to rally more than 90% over the last 24 hours.

The price of XRP tokens has climbed to as much as $0.8661, according to CoinMarketCap.

By reaching this level, the digital currency had risen roughly 91.9% in the space of 24 hours and upwards of 300% from the weekly low of $0.2222 it reached on December 8, additional CoinMarketCap figures show.

Many of the major digital currencies – including Litecoin, Ether and Bitcoin – have generated compelling gains this year as the digital currency market surged higher.

stock market online: Guaranty Bancorp(GBNK)

Advisors’ Opinion:

  • [By WWW.GURUFOCUS.COM]

    For the details of PATRIOT FINANCIAL PARTNERS GP, LP’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=PATRIOT+FINANCIAL+PARTNERS+GP%2C+LP

    These are the top 5 holdings of PATRIOT FINANCIAL PARTNERS GP, LPBanc of California Inc (BANC) – 2,850,564 shares, 27.82% of the total portfolio. Guaranty Bancorp (GBNK) – 1,891,767 shares, 23.36% of the total portfolio. Shares reduced by 19.22%Meta Financial Group Inc (CASH) – 347,069 shares, 14.02% of the total portfolio. Sterling Bancorp (STL) – 1,048,980 shares, 11.07% of the total portfolio. Shares reduced by 16.01%MBT Financial Corp (MBTF) – 2,060,302 sha

stock market online: Shire plc(SHPG)

Advisors’ Opinion:

  • [By Ben Levisohn]

    We highlight the key takeaways below, which have read-throughs for brand drug companies we cover such asAllergan (AGN), Shire (SHPG), Valeant Pharmaceuticals International, Mallinckrodt,Endo International and Jazz Pharmaceuticals (JAZZ), among others.

  • [By Ben Levisohn]

    Specialty pharmaceuticals Shire (SHPG) and Mallinckrodt (MNK) soared today following their better-than-expected earnings, while Morgan Stanley worried about Valeant Pharmaceutical International’s (VRX) ability to sell its unwanted assets.

  • [By Jim Robertson]

    That’s why its worth pointing out that just yesterday, small cap cannabinoid prodrug pharmaceutical stock Vitality Biopharma, Inc. (OTCQB: VBIO) announced the appointment of Tracy Rockney, J.D. to the position of Senior Regulatory Advisor. In addition to being the Co-Founder & Chief Operating Officer of OneSource Regulatory, a regulatory consulting firm, Rockney was previously:

    From May 2010 to May 2015, she was the VP, Regulatory Affairs at AbbVie Inc (NYSE: ABBV) leading the executive functions related to regulatory policy and intelligence. From August 1993 to January 2005, she held positions of increasing responsibility with Pfizer Inc (NYSE: PFE), formerly Wyeth.  From January 2005 to April 2010, she held positions with Shire PLC (NASDAQ: SHPG), including serving as Senior Director, Regulatory Affairs. This included responsibilities as Therapeutic Area Head for Shire’s Gastrointestinal Business Unit, Regulatory Advertising & Promotion and CMC. Rockney led the regulatory team and negotiations with the FDA for LIALDA which are part of the drug class of aminosalicylates that are now part of the clinical standard-of-care for treating inflammatory bowel disease. LIALDA™ was found to be effective in Phase 3 trials for inducing remission of active mild-to-moderate ulcerative colitis after eight weeks of treatment. LIALDA™ (also now marketed as Mezavant®) had 2016 U.S. sales of $714 million – up 16% relative to 2015 sales.

    Rockney’s work for Shire is of particular interest to Vitality Biopharma which has developed a new class of cannabinoid prodrugs (medications or compounds that, after administration, are converted within the body into a pharmacologically active drug), known as cannabosides, which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Cannabosides could provide therapeutic benefits for infl

  • [By Todd Campbell]

    The partnered portfolio includes Movantik and Adynovate, which are licensed to AstraZeneca (NYSE:AZN) and Shire (NASDAQ:SHPG), respectively.

    Movantik won Food and Drug Administration approval in September 2014 for use in relievingopioid constipation, and Nektar Therapeutics reports that annual prescriptions jumped 270% year over year in 2016. Currently, Movantik is selling at an annualized clip of about $160 million, and according to the licensing agreement, Nektar Therapeutics receives a 20% plus royalty on U.S. sales, plus potential sales milestone payments.

stock market online: Nustar Energy L.P.(NS)

Advisors’ Opinion:

  • [By Roberto Pedone]

    One technology player that insiders are active in here is Jive Software (NS), which provides a social business software platform to businesses, government agencies, and other enterprises. Insiders are buying this stock into massive weakness, since shares are down sharply by 43% so far in 2014.

     

    Jive Software has a market cap of $446 million and an enterprise value of $365 million. This stock trades at a fair valuation, with a price-to-sales of 2.68 and a price-to-book of 5.67. Its estimated growth rate for this year is 45.5%, and for next year it’s pegged at 30%. This is a cash-rich company, since the total cash position on its balance sheet is $98.18 million and its total debt is $6.60 million.

     

    A director just bought 260,819 shares, or about $1.71 million worth of stock, at $6.53 to $6.60 per share.

     

    From a technical perspective, JIVE is currently trending just above its 50-day moving average and below its 200-day moving average, which is neutral trendwise. This stock recently pulled back off its short-term high of $7.14 a share with heavy downside volume flows. That drop has now pushed the stock to right above its 50-day moving average at $6.10 a share.

    If you’re bullish on JIVE, then I would look for long-biased trades as long as this stock is trending above its 50-day at $6.10 a share and then once it breaks out above some key near-term overhead resistance levels at $7.14 a share to its 200-day moving average of $7.43 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 557,678 shares. If that breakout triggers soon, then JIVE will set up to re-test or possibly take out its next major overhead resistance levels $8.50 to $9 a share, or even $9.50 to $10 a share.

    Must Read: 10 Stocks George Soros Is Buying

stock market online: Safeway Inc.(SWY)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows shares of SUPERVALU underperforming the underperformance ofmid caps Whole Foods Market, Inc (NASDAQ: WFM) and Safeway Inc (NYSE: SWY). while large capKroger Co (NYSE: KR)had outperformed up until the last two years when performance has been more mixed:

  • [By Peter Graham]

    A long term performance chart shows shares of small cap SUPERVALU now underperforming large cap Kroger Co (NYSE: KR) while shares of large cap Whole Foods Market, Inc (NASDAQ: WFM) and mid cap Safeway Inc (NYSE: SWY) appear to be back to where they started at:

investing basics

The past few days have been utterly painful for shareholders of Frontier Communications (NASDAQ:FTR). After analysts called the company’s dividend into question, shares have fallen sharply — and they have lost almost half of their value since just this January.

Does such a move mean that the company — and its headline-grabbing dividend yield of over 20% — is a buy at today’s prices? Would it be a better bet than putting your money behind a much safer telecom like AT&T (NYSE:T)?

Image source: Getty Images

The answers to these questions aren’t 100% knowable. But we’ll try to examine them by viewing the two companies through three different lenses.

Sustainable competitive advantages

If I had one piece of advice for beginning investors, it would be this: Spend all your time studying sustainable competitive advantages — otherwise known as “moats.” While valuation, industry dynamics, and total addressable markets aren’t unimportant, they pale in comparison with a company’s moat.

investing basics: Preferred Bank(PFBC)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    Preferred Bank (PFBC) has surged 54% in the past year but still trades at a modest discount to the median S&P 1500 regional bank, based on both trailing earnings and estimated 2017 profits.

investing basics: iShares MSCI Europe Financials Sector Index Fund(EUFN)

Advisors’ Opinion:

  • [By Wayne Duggan]

    Investors looking to set up a pair trade to capitalize on the divergent paths of U.S. and European banks should consider going long the iShares Dow Jones US Financial (ETF) (NYSE: IYF) and short the Ishares MSCI Europe Fincls Sctr Indx Fd (NASDAQ: EUFN).

investing basics: TiVo Inc.(TIVO)

Advisors’ Opinion:

  • [By Lisa Levin]

    TiVo Inc. (NASDAQ: TIVO) shares were also up, gaining 21 percent to $9.30. The New York Times, citing sources familiar with the issue, said Rovi Corporation (NASDAQ: ROVI) is in advanced negotiations to acquire TiVo. TiVo shareholders would reportedly receive both cash and stock; however, the price tag is yet to be determined.

  • [By Lisa Levin]

    TiVo Inc. (NASDAQ: TIVO) shares were also up, gaining 20 percent to $9.22. The New York Times reported that Tivo and Rovi Corporation (NASDAQ: ROVI) are in merger talks.

investing basics: Shire plc(SHPG)

Advisors’ Opinion:

  • [By Todd Campbell]

    The partnered portfolio includes Movantik and Adynovate, which are licensed to AstraZeneca (NYSE:AZN) and Shire (NASDAQ:SHPG), respectively.

    Movantik won Food and Drug Administration approval in September 2014 for use in relievingopioid constipation, and Nektar Therapeutics reports that annual prescriptions jumped 270% year over year in 2016. Currently, Movantik is selling at an annualized clip of about $160 million, and according to the licensing agreement, Nektar Therapeutics receives a 20% plus royalty on U.S. sales, plus potential sales milestone payments.

  • [By Ben Levisohn]

    Specialty pharmaceuticals Shire (SHPG) and Mallinckrodt (MNK) soared today following their better-than-expected earnings, while Morgan Stanley worried about Valeant Pharmaceutical International’s (VRX) ability to sell its unwanted assets.

  • [By Max Macaluso and David Williamson]

    At the end of last week, a Bloomberg article revealed that Shire (NASDAQ: SHPG  ) and pharmaceutical giant Sanofi (NYSE: SNY  ) may be circling ViroPharma (NASDAQ: VPHM  ) . The the following video, from The Motley Fool’s health care show Market Checkup, analysts David Williamson and Max Macaluso take a close look at ViroPharma and discuss the recent interest in this small biotech company.

check stock prices

The narrative about U.S. economic growth and financial markets has changed since Donald Trump won the presidential election.

Gone are the days when we talk about central banks, monetary stimulus and low rates. We are in a brave new world of bold fiscal spending plans, tax reforms, rising inflation and rising interest rates.

Whether you are a supporter of the president-elect or not, understanding the implications of the new administration on the economy can be daunting. So weve compiled a list of few prominent economists whose blogs can give you valuable insight.

check stock prices: Old Point Financial Corporation(OPOF)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Wednesday, financial shares fell 0.13 percent. Meanwhile, top losers in the sector included Adams Natural Resources Fund Inc (NYSE: PEO), down 4 percent, and Old Point Financial Corporation (NASDAQ: OPOF) down 3 percent.

check stock prices: Curis, Inc.(CRIS)

Advisors’ Opinion:

  • [By Paul Ausick]

    Curis Inc. (NASDAQ: CRIS) matched a 52-week low of $0.88 set Friday. The 52-week high is $3.48. Volume was about 4 million, four times the daily average of around 1 million. The drugmaker had no specific news Monday.

  • [By Ben Levisohn]

    Skorney’s namesVertex Pharmaceuticals (VRTX),Sarepta Therapeutics (SRPT), and Curis (CRIS) his top biotech picks for 2017, while Ulz chosesBioMarin Pharmaceutical (BMRN) andParatek Pharmaceuticals (PRTK).

  • [By Alex McGuire]

    These are the 10 best penny stocks that have seen the biggest returns over the last week (March 7 – March 14)…

    Penny StockCurrent PriceWeekly Gain (March 7 – March 14)Ocera Therapeutics Inc. (Nasdaq: OCRX)$1.47+147.1%Internap Corp. (Nasdaq: INAP)$3.28+41.4%Soligenix Inc. (Nasdaq: SNGX)$2.94+40%Navios Maritime Partners LP (NYSE: NMM)$2.63+37%QuickLogic Corp. (Nasdaq: QUIK)$2.14+30.5%Adamis Pharmaceuticals Corp. (Nasdaq: ADMP)$4.60+22.7EXCO Resources Inc. (NYSE: XCO)$0.65+20.5%Cyclacel Pharmaceuticals Inc. (Nasdaq: CYCC)$4.38+20.3%Hebron Technology Co. Ltd. (Nasdaq: HEBT)$3.99+19.1%Curis Inc. (Nasdaq: CRIS)$2.85+18.4%

    As a reminder, this is only a tracking metric of penny stocks trading on SEC-regulated exchanges like the Nasdaq and NYSE. Although these top penny stocks are safer than those trading on the pink sheets, we don’t recommend buying any of them without the proper amount of financial research.

check stock prices: U.S. Silica Holdings, Inc.(SLCA)

Advisors’ Opinion:

  • [By Tyler Crowe, Tim Brugger, and Jordan Wathen]

    With that in mind, we asked three of our contributors to highlight a company they will be following closely in the first quarter and why. Here’s what makes Adobe Systems (NASDAQ:ADBE), Charles Schwab (NYSE:SCHW), and U.S. Silica Holdings (NYSE:SLCA) worth following when the next earnings report comes out.

  • [By Peter Graham]

    The Q4 2016 earnings report formid cap proppant and fracking stock U.S. Silica Holdings Inc (NYSE: SLCA)is scheduled for after the market closes onWednesday (February 22nd). Proppant and fracking stockswere crushed by low oil prices; but with oil prices stabilizing, drilling activity coming back to the oil patches.

  • [By Peter Graham]

    A long term performance chart shows shares of CARBO Ceramics performing much worst thanfracking peers U.S. Silica Holdings Inc (NYSE: SLCA) and Hi-Crush Partners LP (NYSE: HCLP) which showed signs of recovery in 2016, but that recoveryhas since fallen off:

check stock prices: (SMPQY)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    We believe that two main risks currently exist. First, a few days ago, U.S. Department of Justice filed charges in generic drug price-fixing probe. The U.S. Department of Justice accused two former generic pharmaceutical executives of colluding with other generic manufacturers to fix prices – the first criminal charges stemming from a two-year investigation. Companies in the congressional probe have since publicly disclosed that they have received subpoenas, including Mylan NV (NASDAQ:MYL), Allergan (NYSE:AGN), which later sold its generics business to Teva (NASDAQ:TEVA), Lannett (NYSEMKT:LCI), Impax Laboratories (NASDAQ:IPXL), Endo International (NASDAQ